112 related articles for article (PubMed ID: 10966754)
21. delta Opioid affinity and selectivity of 4-hydroxy-3-methoxyindolomorphinan analogues related to naltrindole.
Coop A; Rothman RB; Dersch C; Partilla J; Porreca F; Davis P; Jacobson AE; Rice KC
J Med Chem; 1999 May; 42(9):1673-9. PubMed ID: 10229636
[TBL] [Abstract][Full Text] [Related]
22. Syntheses and opioid receptor binding affinities of 8-amino-2,6-methano-3-benzazocines.
Wentland MP; Ye Y; Cioffi CL; Lou R; Zhou Q; Xu G; Duan W; Dehnhardt CM; Sun X; Cohen DJ; Bidlack JM
J Med Chem; 2003 Feb; 46(5):838-49. PubMed ID: 12593663
[TBL] [Abstract][Full Text] [Related]
23. Differential binding properties of oripavines at cloned mu- and delta-opioid receptors.
Lee KO; Akil H; Woods JH; Traynor JR
Eur J Pharmacol; 1999 Aug; 378(3):323-30. PubMed ID: 10493109
[TBL] [Abstract][Full Text] [Related]
24. Potent and Selective Tetrahydroisoquinoline Kappa Opioid Receptor Antagonists of Lead Compound (3 R)-7-Hydroxy- N-[(1 S)-2-methyl-1-(piperidin-1-ylmethyl)propyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (PDTic).
Ondachi PW; Kormos CM; Runyon SP; Thomas JB; Mascarella SW; Decker AM; Navarro HA; Fennell TR; Snyder RW; Carroll FI
J Med Chem; 2018 Sep; 61(17):7525-7545. PubMed ID: 30117738
[TBL] [Abstract][Full Text] [Related]
25. Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of mu-selective agonist and antagonist activity.
McLaughlin JP; Hill KP; Jiang Q; Sebastian A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1999 Apr; 289(1):304-11. PubMed ID: 10087018
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine dependence.
Neumeyer JL; Bidlack JM; Zong R; Bakthavachalam V; Gao P; Cohen DJ; Negus SS; Mello NK
J Med Chem; 2000 Jan; 43(1):114-22. PubMed ID: 10633042
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and in vitro and in vivo activity of (-)-(1R,5R,9R)- and (+)-(1S,5S,9S)-N-alkenyl-, -N-alkynyl-, and -N-cyanoalkyl-5, 9-dimethyl-2'-hydroxy-6,7-benzomorphan homologues.
May EL; Jacobson AE; Mattson MV; Traynor JR; Woods JH; Harris LS; Bowman ER; Aceto MD
J Med Chem; 2000 Dec; 43(26):5030-6. PubMed ID: 11150174
[TBL] [Abstract][Full Text] [Related]
28. Potent and selective indolomorphinan antagonists of the kappa-opioid receptor.
Stevens WC; Jones RM; Subramanian G; Metzger TG; Ferguson DM; Portoghese PS
J Med Chem; 2000 Jul; 43(14):2759-69. PubMed ID: 10893314
[TBL] [Abstract][Full Text] [Related]
29. Novel trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidines as mu opioid receptor antagonists with improved opioid receptor selectivity profiles.
Le Bourdonnec B; Barker WM; Belanger S; Wiant DD; Conway-James NC; Cassel JA; O'Neill TJ; Little PJ; DeHaven RN; DeHaven-Hudkins DL; Dolle RE
Bioorg Med Chem Lett; 2008 Mar; 18(6):2006-12. PubMed ID: 18313920
[TBL] [Abstract][Full Text] [Related]
30. Potent and Selective Tetrahydroisoquinoline Kappa Opioid Receptor Antagonists of Lead Compound (3 R)- N-[1 R)-1-(Cyclohexylmethyl)-2-methylpropyl]-7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (CDTic).
Kormos CM; Ondachi PW; Runyon SP; Thomas JB; Mascarella SW; Decker AM; Navarro HA; Fennell TR; Snyder RW; Carroll FI
J Med Chem; 2018 Sep; 61(17):7546-7559. PubMed ID: 30032602
[TBL] [Abstract][Full Text] [Related]
31. Probes for narcotic receptor mediated phenomena. 44. Synthesis of an N-substituted 4-hydroxy-5-(3-hydroxyphenyl)morphan with high affinity and selective μ-antagonist activity.
Iyer MR; Lee YS; Deschamps JR; Dersch CM; Rothman RB; Jacobson AE; Rice KC
Eur J Med Chem; 2012 Apr; 50():44-54. PubMed ID: 22341895
[TBL] [Abstract][Full Text] [Related]
32. Pharmacodynamic Relationships between Duration of Action of JDTic-like Kappa-Opioid Receptor Antagonists and Their Brain and Plasma Pharmacokinetics in Rats.
Owens SM; Pollard GT; Howard JL; Fennell TR; Snyder RW; Carroll FI
ACS Chem Neurosci; 2016 Dec; 7(12):1737-1745. PubMed ID: 27700049
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes.
Lester PA; Traynor JR
Brain Res; 2006 Feb; 1073-1074():290-6. PubMed ID: 16443205
[TBL] [Abstract][Full Text] [Related]
34. The steroid 17alpha-acetoxy-6-dimethylaminomethyl-21-fluoro-3-ethoxy-pregna-3, 5-dien-20-one (SC17599) is a selective mu-opioid agonist: implications for the mu-opioid pharmacophore.
McFadyen IJ; Houshyar H; Liu-Chen LY; Woods JH; Traynor JR
Mol Pharmacol; 2000 Oct; 58(4):669-76. PubMed ID: 10999935
[TBL] [Abstract][Full Text] [Related]
35. Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorphinones and codeinones.
Nieland NP; Moynihan HA; Carrington S; Broadbear J; Woods JH; Traynor JR; Husbands SM; Lewis JW
J Med Chem; 2006 Aug; 49(17):5333-8. PubMed ID: 16913723
[TBL] [Abstract][Full Text] [Related]
36. The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone.
Beattie DT; Cheruvu M; Mai N; O'Keefe M; Johnson-Rabidoux S; Peterson C; Kaufman E; Vickery R
Naunyn Schmiedebergs Arch Pharmacol; 2007 May; 375(3):205-20. PubMed ID: 17340127
[TBL] [Abstract][Full Text] [Related]
37. Synthesis of novel twin drug consisting of 8-oxaendoethanotetrahydromorphides with a 1,4-dioxane spacer and its pharmacological activities: mu, kappa, and putative epsilon opioid receptor antagonists.
Fujii H; Watanabe A; Nemoto T; Narita M; Miyoshi K; Nakamura A; Suzuki T; Nagase H
Bioorg Med Chem Lett; 2009 Jan; 19(2):438-41. PubMed ID: 19042127
[TBL] [Abstract][Full Text] [Related]
38. Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment.
Wang D; Sun X; Sadee W
J Pharmacol Exp Ther; 2007 May; 321(2):544-52. PubMed ID: 17267582
[TBL] [Abstract][Full Text] [Related]
39. Characterization of N,N(Me)2-Dmt-Tic-OH, a delta selective opioid dipeptide antagonist.
Monory K; Bryant SD; Kertész I; Balboni G; Guerrini R; Tóth G; Salvadori S; Lazarus LH; Borsodi A
Neuroreport; 2000 Jul; 11(10):2083-6. PubMed ID: 10923648
[TBL] [Abstract][Full Text] [Related]
40. Central antinociception induced by ketamine is mediated by endogenous opioids and μ- and δ-opioid receptors.
Pacheco Dda F; Romero TR; Duarte ID
Brain Res; 2014 May; 1562():69-75. PubMed ID: 24675031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
